Journal article
Radiation dosimetry of β-amyloid tracers 11C-PiB and 18F-BAY94-9172
GJ O'Keefe, TH Saunder, S Ng, U Ackerman, HJ Tochon-Danguy, JG Chan, S Gong, T Dyrks, S Lindemann, G Holl, L Dinkelborg, V Villemagne, CC Rowe
Journal of Nuclear Medicine | Published : 2009
Abstract
β-Amyloid (Aβ) imaging has great potential to aid in the diagnosis of Alzheimer disease and the development of therapeutics. The radiation dosimetry of Aβ radioligands may influence their application; therefore, we calculated and compared the effective doses (EDs) of 11C-PiB and a new 18F-labeled ligand, 18F- BAY94-9172. Methods: Attenuation-corrected whole-body scans were performed at 0, 15, 30, 45, and 60 min after injection of 350 ± 28 MBq (mean ± SD) of 11C-PiB in 6 subjects and at 0, 20, 60, 120, and 180 min after injection of 319 ± 27 MBq of 18F-BAY94-9172 in 3 subjects. Coregistered CT was used to define volumes of interest (VOIs) on the PET images. The source organs were the brain, l..
View full abstractGrants
Funding Acknowledgements
We would like to thank Jessica Welch, Jason Bradley, and Kunthi Pathmaraj for their assistance with this study. This work was supported by a grant from Neurosciences Victoria (NSV), which supports the costs of consurnables, overhead, and MRI scans. NSV distributes funds from government and private companies to support neuroscience research in areas of mutual interest. Bayer Schering Pharma is a contributor of funds to NSV and specified that a proportion be used for the development of PET and SPECT AP imaging ligands.